Net Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2023

Earnings Per Share [Abstract]

Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share

The Net loss per share - attributable to PAVmed Inc. - basic and diluted and Net loss per share - attributable to PAVmed Inc. common stockholders - basic and diluted - for the respective periods indicated - is as follows:

	Three Months Ended June 30,						Six Months Ended June 30,
	2023			2022			2023			2022
Numerator
Net loss - before noncontrolling interest	$	(17,892	)	$	(29,101	)	$	(40,106	)	$	(48,734	)
Net loss attributable to noncontrolling interest		3,355			3,576			7,638			6,337
Net loss - as reported, attributable to PAVmed Inc.	$	(14,537	)	$	(25,525	)	$	(32,468	)	$	(42,397	)
Series B Convertible Preferred Stock dividends – earned	$	(75	)	$	(70	)	$	(149	)	$	(138	)
Net loss attributable to PAVmed Inc. common stockholders	$	(14,612	)	$	(25,595	)	$	(32,617	)	$	(42,535	)
Denominator
Weighted average common shares outstanding, basic and diluted		104,349,822			86,957,352			100,742,530			86,689,857
Net loss per share
Basic and diluted
Net loss - as reported, attributable to PAVmed Inc.	$	(0.14	)	$	(0.29	)	$	(0.32	)	$	(0.49	)
Net loss attributable to PAVmed Inc. common stockholders	$	(0.14	)	$	(0.29	)	$	(0.32	)	$	(0.49	)

Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share

	June 30,
	2023		2022
Stock options and restricted stock awards		18,397,406		12,177,406
Series Z Warrants		11,937,450		11,937,450
Series B Convertible Preferred Stock		1,254,497		1,158,950
Total		31,589,353		25,273,806